Welcome

Welcome to the International Journal of Advances in Rheumatology, a CME-accredited quarterly review journal, in print and online, which systematically identifies and highlights the most important recent developments in the assessment and treatment of rheumatic diseases. The journal provides access to a critical and clinically relevant review of information regarding rheumatological medicine, including information pertaining to the diagnosis, treatment, and management of rheumatic diseases.

Each issue of the International Journal of Advances in Rheumatology features in-depth review articles, written by practicing rheumatologists and related disciplines, discussing current and emerging topics of clinical interest (our “Leading Articles”). These articles are commissioned according to relevant themes identified by the Editors-in-Chief, Editorial Advisory Board, and readers. We also present an ongoing, systematic review of key articles selected from the international literature (our “Clinical Reviews”, written by the Editors), expert comment and analysis of specific cases relating to rheumatic disease assessment and management (our “Case Studies”), and reports from the major international meetings.

Please feel free to browse this website. We hope you find the journal informative and interesting. We welcome your comments, letters, and ideas for leading articles, case studies, and meeting reports.

Volume 6 Issue 2

Download complete issue

| Download CME Activity

Leading Articles

Pharmacogenetics of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis: An Update

Hamid Bashir, MD, and Prabha Ranganathan, MD

This review highlights recent literature on the pharmacogenetics of TNF blockers in RA and the issues that surround pharmacogenomic applications.

Cardiovascular Aspects of Rheumatoid Arthritis

Michael T Nurmohamed, MD, PhD

The increased mortality rate in rheumatoid arthritis (RA) is predominantly due to atherosclerotic cardiovascular (CV) disease. This article reviews accumulating evidence that the enhanced CV risk in RA is similar to that observed in type 2 diabetes, and thus RA should be seen as a new CV risk factor for which appropriate risk management is mandatory.

Serum Autoantibodies in Rheumatoid Arthritis

Raimon Sanmartí, MD, Maria Victoria Hernández, MD, José A Gómez-Puerta, MD, Eduard Graell, MD, and Juan D Cañete, MD, PhD

Various antibodies have been found in the sera of patients with rheumatoid arthritis (RA), including rheumatoid factor (RF) and autoantibodies directed against citrullinated peptides that have high specificity and diagnostic and prognostic value. These, together with other autoantibodies found in RA, are discussed in this review.

Case Study

Just Another Case of Neuropsychiatric Systemic Lupus Erythematosus?

Cornelia F Allaart, MD, PhD, Leroy R Lard, MD, PhD, Darius Soonawala, MD, Abraham Schoe, MD, and Irene Speyer, MD

This paper documents the treatment of a 45-year-old woman with persistent convulsions and a history of systemic lupus erythematosus.

Clinical Reviews

Commentary and Analysis on Recent Key Papers

Meeting Report

Annual European Congress of Rheumatology (EULAR 2008)

The Remedica Editorial Team

The Annual European League Against Rheumatism (EULAR) Congress attracts rheumatologists from all over the world and this year >13 000 delegates attended the meeting in Paris, France. A wide range of topics was covered at the Congress, and this report discusses a few of the key presentations.

Other Remedica Publications

Click here for “Highlights” from recent EULAR and ACR meetings, and to obtain CME credit.

For detailed analyses of “Abstracts” from recent international meetings, click here.

Follow this link for a comprehensive analysis of recent advances in the treatment of rheumatic diseases, and to obtain CME credit.